“The prestigious ASLMS Annual Conference represents an important forum
for gathering top clinicians from around the world who have pioneered
the development, study and use of energy-based technologies in
Title: First Clinical Use of Non-Thermal Nano-Pulse
Stimulation Procedure to Eliminate Sebaceous Hyperplasia Lesions by
Date and Time:
Session: Clinical Applications – Cutaneous
Title: High Amplitude, Nanosecond Electrical Pulsing for
Warts by Dr.
Date and Time:
Session: Cutting Edge: Laser and Skin
Times and locations of the presentations are subject to change. Those interested in attending or obtaining information from the presentations are encouraged to visit the ASLMS website at www.aslms.org/annual-conference-2019.
About Nano-Pulse Stimulation
Pulse Biosciences’ patented Nano-Pulse Stimulation™ technology (NPS™), delivered by its proprietary, tunable CellFX System, is characterized by the delivery of a series of nanosecond duration electrical energy pulses, with pulse durations from billionths up to a millionth of a second. This unique non-thermal technology targets cellular structures while sparing non-cellular structures, making it uniquely well suited for cellular targets in the dermis, such as sebaceous glands and other adnexal structures.
Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ System. The Company’s novel CellFX System provides a precise, non-thermal delivery of nanosecond duration energy pulses that impact cells in treated tissue while sparing non-cellular tissue. This unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane, initiating a cascade of events within the cell that results in regulated cell death. The novel characteristics of the Company’s CellFX System has the potential to significantly benefit patients across multiple medical applications, including dermatology, the Company’s first planned commercial application. In pre-clinical studies, Nano-Pulse Stimulation™ (NPS™) technology platform has demonstrated an ability to induce immunogenic cell death in several cancer cell lines. The Company believes its NPS technology platform may play a role in immuno-oncology as a focal tumor treatment that can initiate an adaptive immune response. More information can be found at www.pulsebiosciences.com.
All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements
relating to or implying Pulse Biosciences’ timing of bringing the
CellFX™ System to market and other future events. These statements are
not historical facts but rather are based on Pulse Biosciences’ current
expectations, estimates, and projections regarding Pulse Biosciences’
business, operations and other similar or related factors. You should
not place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions that are
difficult or impossible to predict and, in some cases, beyond Pulse
Biosciences’ control. Actual results may differ materially from those in
the forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with
CAUTION: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) are for investigational use only.
Sr. Vice President and Chief Financial Officer
Gitanjali Jain Ogawa
Nadine D. Tosk, 504-453-8344